We demonstrated that PAI1 expression leads to sensitivity to AZD1208 PIM inhibitor, suggesting that PAI1 expression could be used as a prognosis marker to stratify patients with bad prognosis of the rectal tumors and predict increased efficacy of this PIM inhibitor. The gene discussed is PIM1; the disease is rectal neoplasm.